Trial misses goal: Tonabersat did not significantly reduce central retinal thickness versus placebo after six months in the overall study population. Signals in subgroups: Analyses indicated greater ...
MarketBeat on MSN
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results